Evaxion A/S American Depositary Share EVAX

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

EVAX hizo una agrupación de acciones (split inverso) de 1:5 el 14 de enero de 2025: cada 5 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 2 oct

  Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

  Evaxion will present new immune profiling data from its phase 2 trial of personalized cancer vaccine EVX-01 combined with pembrolizumab at the SITC 2026 Annual Meeting in November. The data will showcase systemic immunomodulatory effects beyond vaccine-specific T-cell responses. Previous two-year data showed a 75% objective response rate in advanced melanoma patients, with 92% still responding at two-year follow-up and no relapses observed.

  

• GlobeNewswire Inc. 12 jul

  Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1

  Evaxion announced new preclinical data supporting its multi-component cytomegalovirus (CMV) vaccine candidate EVX-V1, which combines AI-discovered antigens with optimized established antigens. The data demonstrates potential to improve control of acute infection, latency, and viral reactivation. EVX-V1 represents a scalable strategy for rational vaccine development across herpesviruses, addressing a significant unmet medical need as no CMV vaccine is currently licensed despite affecting 60-70% of adults in developed countries.

  

• GlobeNewswire Inc. 12 jun

  Evaxion receives Prix Galien UK Award for Best digital health solution

  Evaxion A/S received the 2026 Prix Galien UK Award for Best Digital Health Solution for its AI-Immunology™ platform, which uses artificial intelligence to develop novel vaccine candidates for cancer and infectious diseases. This marks the company's second recognition from the Galien Prix Foundation in less than a year, validating the platform's capabilities in vaccine target discovery and development.

  

• GlobeNewswire Inc. 11 jun

  Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia

  Evaxion announced positive preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). The vaccine successfully expresses and secretes in human cells, drives specific immune responses across different human immune profiles, and induces targeted cell-killing. The company is preparing regulatory filings for clinical testing and will present the data at the European Hematology Association Congress in Stockholm on June 13, 2026.